Stem Sel Srl

Stem Sel® Srl is an academic spin-off company with a business based on the development, engineering, manufacturing, and commercialization of the instrument Celector® - the “Cell Chromatograph”. This a totally new instrumentation for the separation, isolation, and collection of living cells with real-time microscopy of the separation process. Celector® does not manipulate cells. The separation process is solely based on differences in the physical properties of the cells. With relevant consumables and disposables, it will be commercialized from mid 2019 for different applications to cell biology/biotech, particularly to multipotent, living stem cell analysis. Celector® is based on a proprietary technology, patented first in Italy (no. IT1371772), and then in North America (8263359US, CA2649234). Patents are property of the University of Bologna, with exclusive license issued to Stem Sel® for the entire duration of the patent. Stem Sel® has also filed an its own patent application (Aug. 2014, for the fluidic device that implements the patented technology. In August 2015, the patent application was extended to PCT (WO2016_027204A1). In Feb. 2016 the patent was issued in Italy, in February 2017 the application was extended to the national phases of Europe, North America, China, South Korea, and Japan, in October 2018 the patent was issued in Canada. Some market figures (2016-2023)- Stem Cells Manufacturing: 9.5-14.6B$; Applications: Research (Drug Discovery & Life Science) 7.4-10.6B$, Clinics 1.6-2.8B$, Cell & Tissue Banks 0.5-1.1B$; Instruments Segment: 1.6-2.2B$, Analogs: 0.5-0.8B$. Expected Celector Market Share: 5-10% of the Analogs. Celector Sales Model: Commercial Partners/Distributors, Revenue Streams from Instruments, Consumables, and Service.